Holbein B - Search Results

1

Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts.

Gerber DE, Hao G, Watkins L, Stafford JH, Anderson J, Holbein B, Öz OK, Mathews D, Thorpe PE, Hassan G, Kumar A, Brekken RA, Sun X. Gerber DE, et al. Among authors: holbein b. Am J Nucl Med Mol Imaging. 2015 Oct 12;5(5):493-503. eCollection 2015. Am J Nucl Med Mol Imaging. 2015. PMID: 26550540 Free PMC article.

2

Institutionally chartered Data and Safety Monitoring Boards: structured approaches to assuring participant safety in clinical research.

Holbein B, Rape MT, Hammack BN, Melvin A, Reider C, Knox TA. Holbein B, et al. J Investig Med. 2021 Jun;69(5):1050-1055. doi: 10.1136/jim-2021-001779. J Investig Med. 2021. PMID: 34074706 Free PMC article.

3

The Hydroxypyridinone Iron Chelator DIBI Reduces Bacterial Load and Inflammation in Experimental Lung Infection.

Zhang X, Nickerson R, Burton L, Stueck A, Holbein B, Cheng Z, Zhou J, Lehmann C. Zhang X, et al. Among authors: holbein b. Biomedicines. 2024 Jun 29;12(7):1452. doi: 10.3390/biomedicines12071452. Biomedicines. 2024. PMID: 39062025 Free PMC article.

4

Iron Metabolism in the Recovery Phase of Critical Illness with a Focus on Sepsis.

Zhang X, Holbein B, Zhou J, Lehmann C. Zhang X, et al. Among authors: holbein b. Int J Mol Sci. 2024 Jun 26;25(13):7004. doi: 10.3390/ijms25137004. Int J Mol Sci. 2024. PMID: 39000113 Free PMC article. Review.

5

Iron Chelation as a Potential Therapeutic Approach in Acute Lung Injury.

Zhang X, Zhou J, Holbein BE, Lehmann C. Zhang X, et al. Among authors: holbein be. Life (Basel). 2023 Jul 30;13(8):1659. doi: 10.3390/life13081659. Life (Basel). 2023. PMID: 37629516 Free PMC article. Review.

6

Iron Withdrawal with DIBI, a Novel 3-Hydroxypyridin-4-One Chelator Iron-Binding Polymer, Attenuates Macrophage Inflammatory Responses.

Ghassemi-Rad J, Fernando W, Holbein BE, Hoskin DW. Ghassemi-Rad J, et al. Among authors: holbein be. Adv Pharm Bull. 2023 Mar;13(2):368-377. doi: 10.34172/apb.2023.040. Epub 2022 Jan 2. Adv Pharm Bull. 2023. PMID: 37342371 Free PMC article.

7

Dysregulated Iron Homeostasis as Common Disease Etiology and Promising Therapeutic Target.

Holbein BE, Lehmann C. Holbein BE, et al. Antioxidants (Basel). 2023 Mar 9;12(3):671. doi: 10.3390/antiox12030671. Antioxidants (Basel). 2023. PMID: 36978919 Free PMC article. Review.

8

Iron Chelator DIBI Suppresses Formation of Ciprofloxacin-Induced Antibiotic Resistance in Staphylococcus aureus.

Allan DS, Holbein BE. Allan DS, et al. Among authors: holbein be. Antibiotics (Basel). 2022 Nov 17;11(11):1642. doi: 10.3390/antibiotics11111642. Antibiotics (Basel). 2022. PMID: 36421286 Free PMC article.

9

Anti-Inflammatory Effects of the Iron Chelator, DIBI, in Experimental Acute Lung Injury.

Lehmann C, Alizadeh-Tabrizi N, Hall S, Faridi S, Euodia I, Holbein B, Zhou J, Chappe V. Lehmann C, et al. Among authors: holbein b. Molecules. 2022 Jun 23;27(13):4036. doi: 10.3390/molecules27134036. Molecules. 2022. PMID: 35807282 Free PMC article.

10

Antimicrobial Activity of the Iron-Chelator, DIBI, against Multidrug-Resistant Canine Methicillin-Susceptible Staphylococcus pseudintermedius: A Preliminary Study of Four Clinical Strains.

Nocera FP, Iovane G, De Martino L, Holbein BE. Nocera FP, et al. Among authors: holbein be. Pathogens. 2022 Jun 7;11(6):656. doi: 10.3390/pathogens11060656. Pathogens. 2022. PMID: 35745511 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

60 results

Search Page

Filters